Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies
Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies
复制标题
DOI：
10.1002/pds.3645
复制
发表时间：
2014-07-01
影响因子：
2.6
通讯作者：
He, Jia
中科院分区：
文献类型：
--
作者：
Chen, Qi;Zhang, Qianwen;He, Jia
目的 探讨钙通道阻滞剂（CCB）与乳腺癌风险增加之间的关联。方法使用乳腺癌和 CCB 相关术语，检索 PubMed、Embase 和 Web of Science 2013 年 7 月之前发表的有关 CCB 使用和乳腺癌相关风险的研究。两名评估者根据预定的选择标准独立选择观察性研究，11 项研究纳入荟萃分析。酌情使用固定效应或随机效应模型获得总结估计，并进行亚组分析、敏感性分析和发表偏倚测试。结果我们的荟萃分析由 11 项研究组成，包括 4 项病例对照、2 项巢式病例对照和 5 项队列研究。 CCB 使用与乳腺癌之间关联的比值比 (OR) 总体为 1.11（95% 置信区间 [CI] 0.93-1.33），前瞻性研究为 1.04（95% CI 0.92-1.18），回顾性研究为 1.33（95% CI 0.79-2.25）。立即释放 CCB 的使用与乳腺癌风险之间存在正相关（OR 1.88，95% CI 1.37-2.60）。结论 没有证据表明 CCB 的使用与乳腺癌风险增加相关。然而，速释CCB的使用与乳腺癌风险之间可能存在正相关，但考虑到目前对缓释CCB的使用偏好，这种相关性的潜在临床影响是有限的。版权所有 (C) 2014 约翰·威利父子有限公司
Objective To investigate the association between calcium channel blockers (CCBs) and increased risk of breast cancer.Methods Using terms related to breast cancer and CCB, we searched PubMed, Embase, and Web of Science for studies on CCB use and the associated risk of breast cancer published before July 2013. Two evaluators independently selected observational studies on the basis of predetermined selection criteria, and 11 studies were included in the meta-analysis. Summary estimates were obtained using fixed-effects or random-effects models as appropriate, and subgroup analyses, sensitivity analyses, and publication bias tests were performed.Results Our meta-analysis consisted of 11 studies, including four case-controls, two nested case-controls, and five cohort studies. The odds ratios (ORs) of the association between CCB use and breast cancer were 1.11 (95% confidence interval [CI] 0.93-1.33) overall, 1.04 (95% CI 0.92-1.18) for prospective studies, and 1.33 (95% CI 0.79-2.25) for retrospective studies. There was a positive association between immediate-release CCB use and risk of breast cancer (OR 1.88, 95% CI 1.37-2.60).Conclusions There is no evidence that CCB use is associated with an increased risk of breast cancer. However, there may be a positive association between immediate-release CCB use and risk of breast cancer, but given the current preference for use of sustained-release CCB, the potential clinical impact of this association is limited. Copyright (C) 2014 John Wiley & Sons, Ltd.